Home|Journals|Articles by Year|Audio Abstracts
 

Original Article



Investigation of Anticancer Effects of Meteorin Like Protein on Different Human Cancer Cell Lines

Suat Tekin, Güldeniz Şekerci, Furkan Yüksel.




Abstract

Objective: Cancer is one of the biggest health problems threatening humanity, and the fight against cancer continues with different methods around the world. Despite advances in cancer prevention and treatment, the low success rate and tumor recurrence make the discovery of new alternative agents important. Adipokines are among those known to be associated with cancer. The relationship of the peptide-structured Meteorin like protein (Metrnl), a member of the adipokine family, discovered in 2012, with cancer remains a mystery. This study was conducted to examine the cytotoxic effects of Metrnl on human ovarian, prostate, colon and breast cancer cell lines.
Materials and Methods: In the study, ovarian (A2780), human prostate (LNCaP), colon (Caco-2) and breast cancer (MCF-7) cell lines were used. After the cells were incubated with 1, 5, 10, 50, 100 and 200 ng/ml concentrations of Metrnl for 24 hours, the cytotoxicity level in the cells was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) assay method. determined. Comparisons between groups were made with the Kruskal Wallis H-Test.
Results: Concentrations of Metrnl significantly reduced cell viability in A2780, LNCaP, Caco-2 and MCF-7 cell lines (p

Key words: Keywords: Meteorin Like Protein, Cytotoxicity, Ovarian Cancer, Prostate Cancer, Colon Cancer, Breast Cancer.






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.